dabrafenib mesilate - Результати пошуку

Швейцарія - німецька - Swissmedic (Swiss Agency for Therapeutic Products)

camzyos 10 mg hartkapseln

bristol-myers squibb sa - mavacamtenum - hartkapseln - mavacamtenum 10 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 0.84 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika

Швейцарія - німецька - Swissmedic (Swiss Agency for Therapeutic Products)

camzyos 15 mg hartkapseln

bristol-myers squibb sa - mavacamtenum - hartkapseln - mavacamtenum 15 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (nigrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 1.26 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika

Європейський Союз - німецька - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brustgeschwulste - endokrine therapie - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.